Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)—A University of Chicago phase II consortium trial.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Maha Hussain, Stephanie Daignault, Przemyslaw Twardowski, Costantine Albany, Mark N. Stein, Lakshmi Priya Kunju, Javed Siddiqui, Dan Robinson, Rohit Mehra, Kathleen A. Cooney, Robert B. Montgomery, Emmanuel S. Antonarakis, Daniel H. Shevrin, Paul Gettys Corn, Young E. Whang, David C. Smith, Megan Veresh Caram, Walter Michael Stadler, Felix Yi-Chung Feng, Arul M. Chinnaiyan
Institutions: University of Michigan, City Of Hope National Medical Center, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Rutgers Cancer Institute, U-M Rogel Cancer Center, Michigan Center for Translational Pathology, University of Washington, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Endeavor Health, The University of Texas MD Anderson Cancer Center, University of North Carolina at Chapel Hill, University of Chicago
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2500493026